Skip to main content
FDA grants priority review of supplemental NDA for leukemia drug
7/17/2017

The FDA will decide by Nov. 9 on the supplemental new drug application for Bristol-Myers Squibb's Sprycel, or dasatinib, as a treatment for pediatric patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia to enhance the powder form of an oral suspension formula.

Full Story: